Top Markets
#1 Wiki Cat Wiki Cat +37.63%
#2 Siren Siren +36.28%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.75%
#4 Velvet Velvet +18.68%
#5 aPriori aPriori +18.66%
#6 PulseChain PulseChain +17.42%
#7 Ribbita by Virtuals Ribbita by Virtuals +15.96%
#8 Janction Janction +14.74%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +14.55%
#10 The Grays Currency The Grays Currency +14.37%
Coin of the day
Wiki Cat Wiki Cat
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD
Kedudukan dalam Saham #30914
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Harga Saham
$0.343985
Modal Pasaran
$15.40M
Perubahan (1 hari)
3.94%
Perubahan (1 tahun)
-25.19%
Negara
BE
Perdagangan Celyad Oncology S.A. (CYAD)

Kategori

Healthcare
Sejarah harga saham bagi Celyad Oncology S.A. (CYAD)
Harga penutupan tertinggi: $0.32 pada 2026-08-01

Harga penutupan terendah: $23.14 pada 2013-07-01
Sejarah harga saham Celyad Oncology S.A. dari 2013 hingga 2026
Prestasi harga saham tahunan
Tahun Prestasi
2026 (TTM) 42.82%
2025 -72.13%
2024 89.47%
2023 -54.51%
2022 -78.81%
2021 -49.40%
2020 -24.66%
2019 -46.68%
2018 -46.75%
2017 106.79%
2016 -61.36%
2015 20.01%
2014 26.03%
2013 0.00%
Harga saham bagi syarikat atau pesaing serupa
Syarikat Harga saham Perubahan 1thn% Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $528.13 35.46%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.01K 52.27%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $111.31 -36.83%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $735.86 6.87%
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $257.87 13.06%
BE